Coherus Oncology replaces senior debt with $55M term loan

What happened

Coherus Oncology, Inc. (NASDAQ: CHRS), a Redwood City, California-based biopharmaceutical company focused on oncology, announced in an 8-K filing on August 17, 2026, that it entered into a new senior secured term loan facility. The company drew the full $55 million on August 14 and used part of the proceeds to repay all outstanding obligations under its previous senior secured term loan agreement, which was terminated the same day.

The new loan, provided by Innovatus Life Sciences Lending Fund I and other lenders, matures in August 2031. It carries a floating interest rate of 4.15% plus the greater of the Prime Rate or 6.75%. The company will make interest-only payments for the first 36 months, with a possible extension to 48 months if it meets certain revenue and market capitalization milestones.

The filing also notes that the company may draw additional tranches of $25 million and $20 million under certain conditions. The prior loan, which was scheduled to mature in May 2029, had an interest rate of 8.0% plus a three-month SOFR rate.

Shares of Coherus rose 16.5% on the filing date to $1.34, with volume about 3.7 times the average, according to price data.

Why it matters

The company stated that the refinancing extends the maturity of its debt beyond the anticipated launch periods for its pipeline product candidates. It also expects the lower interest rate and the increased facility size to provide greater financial flexibility for strategic initiatives.

The new loan is secured by substantially all of the company's assets, including intellectual property. It includes a financial covenant requiring the company to maintain minimum levels of unrestricted cash in collateral accounts, according to the filing.

What this means

An 8-K is a current report that companies file with the SEC to announce major events that shareholders should know about. Item 1.01 covers entering a material agreement, Item 1.02 covers terminating one, and Item 2.03 covers creating a direct financial obligation. All three items apply here because the company simultaneously entered a new loan, repaid and terminated its old one, and took on the new debt.

The new facility is a senior secured term loan, meaning it is a loan backed by the company's assets, and the lender has priority claim over other creditors. The interest rate is floating, so it will change with the Prime Rate. The 6.75% floor means the rate will not fall below 4.15% plus 6.75%, or 10.9%, even if the Prime Rate drops.

The prior loan had an 8.0% rate plus SOFR, which is a benchmark for short-term borrowing costs. By replacing it, Coherus has locked in a lower base rate and pushed the maturity date from 2029 to 2031, giving it more time to generate revenue before the debt comes due. The prepayment fees and final fee are standard costs that would only apply if the company pays off the loan early or defaults.

The company's stock price jumped on the news, which suggests investors viewed the refinancing positively. However, the filing does not explain the price movement, and the company's own statement about benefits is the only rationale provided.